SCYNEXIS Reports Increased Losses and Operating Expenses in Quarterly Filing

SCYNEXIS, Inc. reported significant financial developments in its quarterly filing for the period ending March 31, 2026. The company recorded no revenue from license agreements, a decrease from $257,000 in the same period last year. Operating expenses surged to $16.9 million, up 91% from $8.9 million in the prior year, primarily driven by a $8.0 million expense related to the acquisition of SCY-770, an AMP-activated protein kinase activator for treating Autosomal Dominant Polycystic Kidney Disease (ADPKD). The net loss for the quarter was $21.3 million, compared to a loss of $5.4 million in the first quarter of 2025, reflecting a 295% increase in losses year-over-year.

The company’s total assets increased to $77.6 million as of March 31, 2026, up from $59.0 million at the end of 2025, largely due to a rise in cash and cash equivalents, which reached $36.7 million, compared to $21.3 million at the end of the previous year. This increase was bolstered by a successful private placement that raised $40 million in gross proceeds, with net proceeds of approximately $37.2 million after expenses. The company’s accumulated deficit also grew to $406.4 million, reflecting ongoing investments in research and development.

In terms of strategic developments, SCYNEXIS completed an asset purchase agreement with Poxel SA, acquiring rights to SCY-770, which has received Orphan Drug Designation from the FDA. The company plans to initiate a Phase 2 proof-of-concept study for SCY-770 in ADPKD patients in late 2026, with an early efficacy readout expected in 2027. Additionally, SCYNEXIS is advancing SCY-247, another antifungal candidate, which is currently in a Phase 1 trial.

Operationally, SCYNEXIS reported a total of 62,051,330 shares outstanding as of March 31, 2026, a significant increase from 43,541,510 shares at the end of 2025. The company’s employee headcount has also seen fluctuations, impacting its operational expenses. The filing indicates that SCYNEXIS is focused on expanding its product pipeline and enhancing its market position in the biotech sector, particularly in the treatment of rare diseases.

Looking ahead, SCYNEXIS anticipates continued significant expenses related to its research and development activities. The company believes its current capital resources are sufficient to fund operations for at least the next 12 months, but it will require additional funding to support ongoing and future projects. The management remains optimistic about the potential of SCY-770 and SCY-247, emphasizing the unmet medical needs in their respective markets.